John J Mariani1, Frances R Levin. 1. Division on Substance Abuse, New York State Psychiatric Institute, New York, New York 10032, USA. jm2330@columbia.edu
Abstract
OBJECTIVES: Alcohol dependence is frequently associated with anxiety disorders. The exact nature of the relationship between alcohol dependence and anxiety disorders is unknown, but emerging evidence suggests that in a majority of cases, the anxiety disorder is independent of the alcohol use disorder. There is pre-clinical and clinical evidence that levetiracetam, a newer generation anticonvulsant medication, may be efficacious in the treatment of co-occurring alcohol use and anxiety disorders. METHODS: In an open label clinical trial, three patients with alcohol dependence and a co-morbid anxiety disorder were treated with levetiracetam in doses up to 1500 mg twice daily for up to 8 weeks. RESULTS: All three participants reported reductions in alcohol consumption and anxiety symptoms during the study period. Levetiracetam was generally well tolerated. CONCLUSION: This study suggests that levetiracetam deserves further study in the treatment of alcohol dependence and co-occurring anxiety disorders.
OBJECTIVES:Alcohol dependence is frequently associated with anxiety disorders. The exact nature of the relationship between alcohol dependence and anxiety disorders is unknown, but emerging evidence suggests that in a majority of cases, the anxiety disorder is independent of the alcohol use disorder. There is pre-clinical and clinical evidence that levetiracetam, a newer generation anticonvulsant medication, may be efficacious in the treatment of co-occurring alcohol use and anxiety disorders. METHODS: In an open label clinical trial, three patients with alcohol dependence and a co-morbid anxiety disorder were treated with levetiracetam in doses up to 1500 mg twice daily for up to 8 weeks. RESULTS: All three participants reported reductions in alcohol consumption and anxiety symptoms during the study period. Levetiracetam was generally well tolerated. CONCLUSION: This study suggests that levetiracetam deserves further study in the treatment of alcohol dependence and co-occurring anxiety disorders.
Authors: C L Randall; M R Johnson; A K Thevos; S C Sonne; S E Thomas; S L Willard; K T Brady; J R Davidson Journal: Depress Anxiety Date: 2001 Impact factor: 6.505
Authors: U Schneider; A Altmann; M Baumann; J Bernzen; B Bertz; U Bimber; T Broese; A Broocks; W Burtscheidt; K F Cimander; P Degkwitz; M Driessen; H Ehrenreich; E Fischbach; H Folkerts; H Frank; D Gurth; U Havemann-Reinecke; W Heber; J Heuer; A Hingsammer; S Jacobs; H Krampe; W Lange; T Lay; M Leimbach; M R Lemke; M Leweke; A Mangholz; W Massing; R Meyenberg; J Porzig; T Quattert; C Redner; G Ritzel; J D Rollnik; R Sauvageoll; D Schläfke; G Schmid; H Schröder; U Schwichtenberg; D Schwoon; J Seifert; I Sickelmann; C F Sieveking; C Spiess; H H Stiegemann; R Stracke; H D Straetgen; P Subkowski; R Thomasius; H Tretzel; L J Verner; J Vitens; T Wagner; S Weirich; I Weiss; T Wendorff; T Wetterling; B Wiese; J Wittfoot Journal: Alcohol Alcohol Date: 2001 May-Jun Impact factor: 2.826
Authors: Bankole A Johnson; Nassima Ait-Daoud; Charles L Bowden; Carlo C DiClemente; John D Roache; Kevin Lawson; Martin A Javors; Jennie Z Ma Journal: Lancet Date: 2003-05-17 Impact factor: 79.321
Authors: Joanne B Fertig; Megan L Ryan; Daniel E Falk; Raye Z Litten; Margaret E Mattson; Janet Ransom; William J Rickman; Charles Scott; Domenic Ciraulo; Alan I Green; Nassima A Tiouririne; Bankole Johnson; Helen Pettinati; Eric C Strain; Eric Devine; Mary F Brunette; Kyle Kampman; David A Tompkins; Robert Stout Journal: Alcohol Clin Exp Res Date: 2012-02-10 Impact factor: 3.455
Authors: Eric W Fish; Abigail E Agoglia; Michael C Krouse; R Grant Muller; J Elliott Robinson; C J Malanga Journal: Behav Pharmacol Date: 2014-02 Impact factor: 2.293
Authors: J Elliott Robinson; Meng Chen; Alice M Stamatakis; Michael C Krouse; Elaina C Howard; Sara Faccidomo; Clyde W Hodge; Eric W Fish; C J Malanga Journal: Neuropsychopharmacology Date: 2013-01-25 Impact factor: 7.853
Authors: Madeeha Nasir; Daniel Trujillo; Jessica Levine; Jennifer B Dwyer; Zachary W Rupp; Michael H Bloch Journal: Front Psychiatry Date: 2020-11-19 Impact factor: 4.157